TARGETing steroid withdrawal in SLE (TARGET2020 STUDY): a pragmatic, randomized, phase IV, open-label, non-inferiority trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518580-35-00

Acronym

TARGET2020

Enrollment

252

Registered

2024-11-19

Start date

2024-11-20

Completion date

Unknown

Last updated

2025-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Brief summary

Proportion of patients maintaining modified LLDAS for 100% of the follow-up period (36 months) even after glucocorticoid withdrawal

Detailed description

o Proportion of patients who maintain modified LLDAS for 100% of the visits at 12, 24 and 36 months o Proportion of patients who maintain remission on treatment for 100% of the visits at 12, 24 and 36 months

Interventions

DRUGPrednisone Mylan Pharma 5 mg compresse

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportion of patients maintaining modified LLDAS for 100% of the follow-up period (36 months) even after glucocorticoid withdrawal	—

Secondary

Measure	Time frame
o Proportion of patients who maintain modified LLDAS for 100% of the visits at 12, 24 and 36 months o Proportion of patients who maintain remission on treatment for 100% of the visits at 12, 24 and 36 months	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026